Search Results

Predictors of survival and recurrence patterns following definitive chemoradiotherapy in stage III non-small cell lung cancer-a retrospective cohort study

• Authors : Brostrom, E; Isaksson, J; Xanthoulis, P

• Source: TRANSLATIONAL LUNG CANCER RESEARCH. 14(6):1972-1985

Record details

Based on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Study on Safety and Efficacy

• Source: Based on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal

Record details

Iparomlimab and tuvonralimab (QL1706) combined definitive chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma (QL1706-IIT-02): a single arm, phase 2 trialResearch in context

• Authors : Wencheng Zhang; Tian Zhang; Xi Chen

Subjects: Esophageal squamous cell carcinoma; Definitive chemoradiotherapy; PD-1

• Source: EClinicalMedicine, Vol 92, Iss , Pp 103758- (2026)

Record details

Real-world clinical characteristics and outcomes of patients with locally advanced, unresectable esophageal/gastroesophageal junction cancer treated with definitive chemoradiotherapy in the United States community oncology setting

• Authors : Adriana Valderrama; Karthik Ramakrishnan; Lisa Herms

Subjects: locally advanced esophageal cancer; gastric or gastroesophageal junction cancer; survival analysis

• Source: Frontiers in Oncology, Vol 15 (2026)

Record details

Assessing the Efficacy and Safety of Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy (PET-BOOST)

• Authors : David Palma, Principal Investigator

• Source: A Randomized Phase II Trial to Assess the Efficacy and Safety of Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-Small Cell Lung Cancer Receiving

Record details

Definitive chemoradiotherapy combined with anti-PD-1 immunotherapy for inoperable esophageal squamous cell carcinoma: a multicenter real-world study

• Authors : Xiongtao Yang; Xiaomin Wang; Qin Xiao

Subjects: Immunotherapy; definitive chemoradiotherapy; inoperable esophageal cancer

• Source: Cancer Biology & Therapy, Vol 26, Iss 1 (2025)

Record details

Integrated circulating tumor DNA-based prognostic algorithm for limited stage small-cell lung cancer under definitive chemoradiotherapy and utility in consolidation immunotherapy benefit prediction.

• Authors : Fu, Yao^1,2 (AUTHOR); Zhou, Jianming³ (AUTHOR); Chen, Xiaoxi⁴ (AUTHOR)

• Source: Cell Communication & Signaling. 11/7/2025, Vol. 23 Issue 1, p1-13. 13p.

Record details

A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

• Authors : GORTEC (Head and Neck Oncology and Radiotherapy Group); Merck KGaA, Darmstadt, Germany

• Source: A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With

Record details

Symptoms Burden in Lung Cancer Patients Undergoing Definitive Chemoradiotherapy: Insights From Electronic Patient-Reported Outcomes (ePRO-LC-CRT)

• Authors : Qian Chu, Professor

• Source: A Prospective Observational Study on Symptom Burden in Lung Cancer Patients Undergoing Definitive Chemoradiotherapy: Insights From

Record details

Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed: The Study Protocol for the Randomized Controlled NEEDS Trial

• Authors : Nilsson, Magnus; Olafsdottir, Halla; Alexandersson von Döbeln, Gabriella

Subjects: definitive chemoradiotherapy; esophageal squamous cell carcinoma; locoregional surveillance

• Source: Frontiers in Oncology. 12

Record details